サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1786389

認知症治療の世界市場

Dementia Treatment

出版日
ページ情報
英文 204 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
認知症治療の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 204 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

認知症治療の世界市場は2030年までに301億米ドルに達する見込み

2024年に195億米ドルと推定される認知症治療の世界市場は、2024年から2030年にかけてCAGR 7.5%で成長し、2030年には301億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるアルツハイマー型認知症の適応症は、CAGR 8.1%を記録し、分析期間終了までに171億米ドルに達すると予測されます。血管性認知症適応症セグメントの成長率は、分析期間中CAGR 7.1%と推定されます。

米国市場は51億米ドルと推定、中国はCAGR 7.3％で成長予測

米国の認知症治療市場は2024年に51億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに48億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは7.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.0％と6.3％と予測されています。欧州では、ドイツがCAGR約6.0%で成長すると予測されています。

世界の認知症治療市場- 主要動向と促進要因まとめ

認知症負担の増加は治療展望をどのように形成しているか？

認知症は世界の健康上の重要課題として浮上しており、高齢化によって患者数が急増しています。世界保健機関（WHO）によると、世界中で5,500万人以上が認知症を患っており、その数は2050年までにほぼ3倍になると予想されています。認知症患者の60～70％を占めるアルツハイマー病の有病率の増加は、効果的な治療に対する需要を高めています。根治療法がないため、早期診断、対症療法、疾患修飾介入が重要な焦点となっています。世界中のヘルスケアシステムが認知症の社会経済的負担に苦慮しており、政府や製薬会社は研究開発（R&D）の取り組みを加速させています。認知症に対する薬剤開発は、神経変性の複雑さゆえに特に困難であるが、最近のモノクローナル抗体治療薬、アミロイドβ阻害薬、タウ蛋白標的薬などの画期的な動向は、疾患の進行を遅らせる希望をもたらしています。さらに、認知療法、脳刺激療法、生活習慣の改善などの非薬理学的介入も、補完的な治療法として注目されています。高度な画像診断、血液バイオマーカー、AIを活用した診断による早期発見が重視され、不可逆的な認知機能低下が起こる前にタイムリーな介入が可能となり、認知症治療に変革をもたらしつつあります。

認知症治療を変革する新たな治療法は？

認知症治療を取り巻く環境は、対症療法から疾患修飾療法へのシフトを目の当たりにしており、革新的な薬剤が相次いで臨床試験に参入しています。アデュカヌマブやレカネマブといったアミロイドを標的とする薬剤が最近承認されたことで、その有効性や費用対効果について議論があるにもかかわらず、新たな可能性が開かれました。脳からアミロイド斑を除去するように設計されたモノクローナル抗体は、疾患修飾治療の可能性として検討されています。神経原線維のもつれ形成を防ぐことを目的としたタウ蛋白阻害剤も、後期臨床試験で勢いを増しています。さらに、コリンエステラーゼ阻害薬とNMDA受容体拮抗薬は、認知症状の管理に不可欠です。薬理学的な解決策にとどまらず、経頭蓋磁気刺激（TMS）、脳深部刺激（DBS）、遺伝子治療などの新しい治療法が、疾患の進行を遅らせることに有望視されています。精密医療やバイオマーカー主導の治療アプローチへの関心の高まりは、認知症治療の展望をさらに変えつつあります。企業はRNAベースの薬剤、幹細胞治療、長期的な効果が期待できる神経保護剤に多額の投資を行っています。一方、AIを活用した認知トレーニングプログラムやウェアラブルバイオセンサーを含むデジタル治療薬の台頭は、継続的なモニタリングと介入を可能にし、患者の転帰を向上させています。

規制と市場力学は認知症治療薬開発にどのような影響を与えているか？

規制当局は、革新的な治療に対する緊急のニーズと安全性および有効性の懸念とのバランスを取りながら、認知症治療市場を形成する上で極めて重要な役割を果たしています。米国食品医薬品局（FDA）によるアミロイド標的薬の早期承認は、認知症治療薬の早期承認に関する議論を呼び起こしました。しかし、価格設定と償還の課題は依然として大きなハードルであり、高コストの治療薬は利用しやすさを制限しています。欧州医薬品庁（EMA）をはじめとする世界の規制当局は、厳格な臨床試験を重視し、広く承認される前に認知機能の改善に関する決定的な証拠を要求しています。一方、官民パートナーシップの台頭により、学界、バイオテクノロジー企業、製薬大手間の協力体制が強化され、研究のブレークスルーが加速しています。遺伝子やバイオマーカーのプロファイリングに基づく標的治療が普及するにつれ、個別化医療への注目の高まりは規制の枠組みにも影響を及ぼしています。さらに、政府や非営利団体は、認知症のヘルスケア負担が増大していることを認識し、これまでにないレベルで認知症研究に資金を提供しています。認知症治療薬の臨床試験の失敗率の高さは依然として課題であるが、AIを活用した創薬や革新的な臨床試験デザインの進歩により成功率が向上し、治療パイプラインが再構築されつつあります。

認知症治療市場の成長を促進する要因とは？

認知症治療市場の成長は、主に平均寿命の伸びによる認知症の世界の有病率の上昇など、いくつかの要因によって牽引されています。早期診断と早期介入への需要が急増し、バイオマーカーに基づく診断やAIを活用したスクリーニングツールへの注目が高まっています。特にアミロイドやタウを標的とした疾患修飾薬の導入は、製薬企業に新たな収益源をもたらしました。さらに、在宅医療や遠隔医療ソリューションの拡大により、遠隔地の患者にも対応した認知症治療へのアクセスが増加しています。神経画像や血液ベースのバイオマーカーの進歩により早期発見が強化され、患者は不可逆的なダメージが生じる前に治療の恩恵を受けることができます。デジタル治療薬、認知トレーニングアプリ、スマートモニタリングデバイスの採用が増加しており、従来の治療アプローチをさらに補完しています。さらに、政府の取り組み、ヘルスケア支出の増加、神経変性研究への資金提供の増加により、より強固なエコシステムが形成されつつあります。遺伝子やバイオマーカーに基づく治療を活用した精密医療の出現は、今後数年間で認知症治療に革命をもたらし、市場を急拡大させることが期待されます。

セグメント

適応症（アルツハイマー型認知症適応症、血管性認知症適応症、レビー小体型認知症適応症、前頭側頭型認知症（FTD）適応症、パーキンソン病認知症適応症、その他の適応症）、薬剤クラス（コリンエステラーゼ阻害薬クラス、NMDA受容体拮抗薬クラス、MAO阻害薬クラス、併用薬クラス、その他の薬剤クラス）、投与経路（経口投与経路、経皮パッチ投与経路、注射投与経路）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • Biogen Inc.
  • Cipla Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Cadila

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMにクエリーする代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP30409

Global Dementia Treatment Market to Reach US$30.1 Billion by 2030

The global market for Dementia Treatment estimated at US$19.5 Billion in the year 2024, is expected to reach US$30.1 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Alzheimer's Disease Dementia Indication, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$17.1 Billion by the end of the analysis period. Growth in the Vascular Dementia Indication segment is estimated at 7.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 7.3% CAGR

The Dementia Treatment market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.

Global Dementia Treatment Market - Key Trends & Drivers Summarized

How Is the Rising Dementia Burden Shaping the Treatment Landscape?

Dementia has emerged as a significant global health challenge, with an aging population driving a surge in cases. According to the World Health Organization (WHO), over 55 million people worldwide are living with dementia, a number expected to nearly triple by 2050. The increasing prevalence of Alzheimer's disease, which accounts for 60-70% of dementia cases, has intensified the demand for effective treatments. The lack of curative therapies has made early diagnosis, symptomatic management, and disease-modifying interventions the key focus areas. Healthcare systems worldwide are struggling with the socio-economic burden of dementia, prompting governments and pharmaceutical companies to accelerate research and development (R&D) efforts. Drug development for dementia is particularly challenging due to the complexity of neurodegeneration, but recent breakthroughs in monoclonal antibody therapies, amyloid-beta inhibitors, and tau protein-targeting drugs offer hope for slowing disease progression. Additionally, non-pharmacological interventions such as cognitive therapies, brain stimulation, and lifestyle modifications are gaining attention as complementary treatment options. The emphasis on early detection through advanced imaging, blood biomarkers, and AI-driven diagnostics is transforming dementia treatment, enabling timely intervention before irreversible cognitive decline occurs.

Which Emerging Therapies Are Transforming Dementia Treatment?

The dementia treatment landscape is witnessing a shift from symptomatic management to disease-modifying therapies, with a wave of innovative drugs entering clinical trials. The recent approvals of amyloid-targeting drugs such as Aducanumab and Lecanemab have opened new possibilities, despite debates over their efficacy and cost-effectiveness. Monoclonal antibodies designed to clear amyloid plaques from the brain are being explored as potential disease-modifying treatments. Tau protein inhibitors, aimed at preventing neurofibrillary tangle formation, are also gaining momentum in late-stage trials. Additionally, cholinesterase inhibitors and NMDA receptor antagonists remain essential for managing cognitive symptoms. Beyond pharmacological solutions, novel therapies such as transcranial magnetic stimulation (TMS), deep brain stimulation (DBS), and gene therapy are showing promise in slowing disease progression. The growing interest in precision medicine and biomarker-driven treatment approaches is further transforming the dementia therapy landscape. Companies are investing heavily in RNA-based drugs, stem cell therapy, and neuroprotective agents that could offer long-term benefits. Meanwhile, the rise of digital therapeutics, including AI-powered cognitive training programs and wearable biosensors, is enabling continuous monitoring and intervention, enhancing patient outcomes.

How Are Regulatory and Market Dynamics Influencing Dementia Drug Development?

Regulatory agencies play a crucial role in shaping the dementia treatment market, balancing the urgent need for innovative therapies with safety and efficacy concerns. The accelerated approval of amyloid-targeting drugs by the U.S. Food and Drug Administration (FDA) has sparked discussions about fast-tracking dementia drug approvals. However, pricing and reimbursement challenges remain significant hurdles, with high-cost therapies limiting accessibility. The European Medicines Agency (EMA) and other global regulators are emphasizing rigorous clinical trials, demanding conclusive evidence of cognitive improvement before widespread approvals. Meanwhile, the rise of public-private partnerships is fostering greater collaboration between academia, biotech firms, and pharmaceutical giants, accelerating research breakthroughs. The increasing focus on personalized medicine is also influencing regulatory frameworks, as targeted therapies based on genetic and biomarker profiling gain traction. Additionally, governments and non-profit organizations are funding dementia research at unprecedented levels, recognizing its growing healthcare burden. While the high failure rate of dementia drug trials remains a challenge, advancements in AI-driven drug discovery and innovative clinical trial designs are improving success rates, reshaping the treatment pipeline.

What Factors Are Driving Growth in the Dementia Treatment Market?

The growth in the dementia treatment market is driven by several factors, primarily the rising global prevalence of dementia due to increasing life expectancy. The demand for early diagnosis and intervention has surged, leading to a growing focus on biomarker-based diagnostics and AI-powered screening tools. The introduction of disease-modifying drugs, particularly amyloid and tau-targeting therapies, has opened new revenue streams for pharmaceutical companies. Additionally, the expansion of home-based care and telemedicine solutions has increased access to dementia treatments, catering to patients in remote areas. Advances in neuroimaging and blood-based biomarkers are enhancing early detection, allowing patients to benefit from treatments before irreversible damage occurs. The increasing adoption of digital therapeutics, cognitive training apps, and smart monitoring devices is further complementing traditional treatment approaches. Furthermore, government initiatives, rising healthcare spending, and increased funding for neurodegenerative research are fostering a more robust dementia treatment ecosystem. The emergence of precision medicine, leveraging genetic and biomarker-based therapies, is expected to revolutionize dementia treatment in the coming years, positioning the market for rapid expansion.

SCOPE OF STUDY:

The report analyzes the Dementia Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication, Frontotemporal Dementia (FTD) Indication, Parkinson Disease Dementia Indication, Other Indications); Drug Class (Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class, Other Drug Classes); Route of Administration (Oral Route of Administration, Transdermal Patch Route of Administration, Injectable Route of Administration); Distribution Channel (Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels, Online Pharmacy Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AbbVie Inc.
  • Aurobindo Pharma Ltd.
  • Biogen Inc.
  • Cipla Inc.
  • Daiichi Sankyo Company, Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • H. Lundbeck A/S
  • Johnson & Johnson Services, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Cadila

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Dementia Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Aging Population Trends Throw the Spotlight on Dementia as a Growing Public Health Challenge
    • Rising Prevalence of Alzheimer's and Other Neurodegenerative Disorders Spurs Innovation in Disease-Modifying Therapies
    • Approval of Novel Monoclonal Antibody Treatments Strengthens the Business Case for Early-Stage Intervention
    • Increased Investment in Cognitive Health Fuels Pipeline Development in Small Molecule and Biologic Therapies
    • Shift Toward Personalized Medicine Supports Use of Biomarkers and Genetic Screening in Dementia Diagnosis
    • Expansion of Digital Therapeutics and Cognitive Training Platforms Enhances Non-Pharmacological Treatment Options
    • Growing Use of AI in Early Detection and Imaging Analysis Accelerates Diagnosis and Monitoring
    • Caregiver Burnout and Healthcare Burden Create Opportunities for In-Home and Community-Based Treatment Solutions
    • Improved Access to Memory Clinics and Cognitive Screening Tools Drives Diagnosis Rates Globally
    • Rising Participation in Clinical Trials and Real-World Evidence Studies Supports Regulatory Momentum
    • Pharma and Tech Partnerships Expand Cross-Disciplinary Approaches to Dementia Care
    • Health Policy Initiatives and National Dementia Plans Support Funding for Innovative Care Models
    • Increased Focus on Lifestyle Interventions and Nutrition Opens Holistic Treatment Opportunities
    • Integration of Telehealth in Neurology and Geriatrics Supports Remote Monitoring and Medication Adherence
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Dementia Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Dementia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Dementia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Alzheimer's Disease Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Alzheimer's Disease Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Vascular Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Vascular Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lewy Body Dementia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Lewy Body Dementia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Frontotemporal Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Frontotemporal Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oral Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oral Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Transdermal Patch Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Transdermal Patch Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Injectable Route of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Injectable Route of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Hospital Pharmacy Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Hospital Pharmacy Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacy Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Retail Pharmacy Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Online Pharmacy Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Online Pharmacy Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitor Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Cholinesterase Inhibitor Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for NMDA Receptor Antagonist Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for NMDA Receptor Antagonist Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for MAO Inhibitor Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for MAO Inhibitor Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Combination Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Combination Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 34: USA Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 40: USA Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: USA 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • CANADA
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 48: Canada Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Canada 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • JAPAN
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • CHINA
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 58: China Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 64: China Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: China 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • EUROPE
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Dementia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • FRANCE
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 76: France Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 82: France Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: France 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • GERMANY
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 90: Germany Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Germany 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • UNITED KINGDOM
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 100: UK Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 106: UK Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: UK 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Rest of Europe 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Dementia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Indication - Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Dementia Treatment by Indication - Percentage Breakdown of Value Sales for Alzheimer's Disease Dementia Indication, Vascular Dementia Indication, Lewy Body Dementia Indication and Frontotemporal Dementia for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Route Of Administration - Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Dementia Treatment by Route Of Administration - Percentage Breakdown of Value Sales for Oral Route of Administration, Transdermal Patch Route of Administration and Injectable Route of Administration for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Distribution Channel - Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Dementia Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy Distribution Channels, Retail Pharmacy Distribution Channels and Online Pharmacy Distribution Channels for the Years 2025 & 2030
    • TABLE 130: Rest of World Recent Past, Current & Future Analysis for Dementia Treatment by Drug Class - Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of World 6-Year Perspective for Dementia Treatment by Drug Class - Percentage Breakdown of Value Sales for Cholinesterase Inhibitor Drug Class, NMDA Receptor Antagonist Drug Class, MAO Inhibitor Drug Class, Combination Drug Class and Other Drug Classes for the Years 2025 & 2030

IV. COMPETITION